Petr Jarolim

Petr Jarolim

Auto-generated profile, based on publicly available information

Petr Jarolim

Pathology, Brigham and Women’s Hospital, Boston, MA (P.J.).

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NMNicholas A Marston
Nicholas A Marston
AGAmanda C Garfinkel
Amanda C Garfinkel
FKFrederick K Kamanu
Frederick K Kamanu
GMGiorgio M Melloni
Giorgio M Melloni
CRCarolina Roselli
Carolina Roselli
CRChristian T Ruff
Christian T Ruff
Interest in targeted screening programmes for atrial fibrillation (AF) has increased, yet the role of genetics in identifying patients at highest risk of developing AF is unclear. A total of 36,662 subjects without prior AF were analyzed from four TIMI trials. Subjects were divided into quintiles using a validated polygenic risk score (PRS) for AF. Clinical risk for AF was calculated using the CHARGE-AF model. Kaplan–Meier event rates, adjusted hazard ratios (HRs), C-indices, and net reclassification improvement were used to determine if the addition of the PRS improved prediction compared with clinical risk and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Over 2.3 years, 1018 new AF cases developed. AF PRS predicted a significant risk gradient for AF with a 40% increased risk per 1-SD increase in PRS [HR: 1.40 (1.32–1.49); P < 0.001]. Those with high AF PRS (top 20%) were more than two-fold more likely to develop AF [HR 2.45 (1.99–3.03), P < 0.001] compared with low PRS (bottom 20%). Furthermore, PRS provided an additional gradient of risk stratification on top of the CHARGE-AF clinical risk score, ranging from a 3-year incidence of 1.3% in patients with low clinical and genetic risk to 8.7% in patients with high clinical and genetic risk. The subgroup of patients with high clinical risk, high PRS, and elevated NT-proBNP had an AF risk of 16.7% over 3 years. The C-index with the CHARGE-AF clinical risk score alone was 0.65, which improved to 0.67 (P < 0.001) with the addition of NT-proBNP, and increased further to 0.70 (P < 0.001) with the addition of the PRS. In patients with cardiovascular conditions, AF PRS is a strong independent predictor of incident AF that provides complementary predictive value when added to a validated clinical risk score and NT-proBNP. Classification of study population by genetic, clinical, and biomarker risk for atrial fibrillation (AF). PRS, polygenic risk score; CHARGE-AF, Cohorts for Heart and Aging Research in Genomic Epidemiology for Atrial Fibrillation (risk score including age, height, weight, systolic blood pressure, diastolic blood pressure, current tobacco use, antihypertensive medication use, diabetes, heart failure, and prior myocardial infarction). Rates of incident AF by genetic, clinical, and biomarker risk categories are shown.

30 May 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
PJPetr Jarolim
Petr Jarolim
WWWilliam B. White
William B. White
CCChristopher P. Cannon
Christopher P. Cannon
QGQi Gao
Qi Gao
DMDavid A. Morrow
David A. Morrow
OBJECTIVE Patients with type 2 diabetes are at increased risk of developing heart failure (HF). Enhanced recognition of patients at risk for HF would help guide therapeutic decisions. RESEARCH DESIGN AND METHODS We investigated the prognostic implications of changes in N-terminal B-type natriuretic peptide (NT-proBNP) concentration in patients with type 2 diabetes and ischemic heart disease who were enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, a phase 3b trial of alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor. Patients with type 2 diabetes and a recent acute coronary syndrome event were eligible. NT-proBNP was measured at baseline and 6 months. Cardiovascular (CV) death or hospitalization for HF was the end point of principal interest for this analysis. RESULTS We observed a strong graded relationship between increasing baseline and 6-month NT-proBNP concentration and the incidence of major CV events (P < 0.001). After adjusting for potential confounders, NT-proBNP at baseline was independently associated with the development of major CV events, in particular hospitalization for HF. Patients who had persistently high NT-proBNP (P < 0.001) or developed high NT-proBNP at 6 months (P < 0.001) were at a significantly higher risk for CV death/HF than those in whom NT-proBNP remained low at both time points or who had a high NT-proBNP value at baseline that subsequently declined to the low category. Absolute changes in NT-proBNP by 6 months were also strongly associated with subsequent outcomes. Treatment with a DPP-4 inhibitor did not meaningfully alter NT-proBNP concentrations (P = 0.20). CONCLUSIONS Serial monitoring of NT-proBNP in patients with type 2 diabetes and ischemic heart disease may be useful for identifying patients at highest risk for HF.

1 April 2019 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
JBJan Benes
Jan Benes
MKMartin Kotrc
Martin Kotrc
PWPeter Wohlfahrt
Peter Wohlfahrt
MCMichael J. Conrad
Michael J. Conrad
JFJanka Franekova
Janka Franekova
PJPetr Jarolim
Petr Jarolim

13 October 2015 in Circulation
Verified
Journal Article
Open access
BSBenjamin M. Scirica
Benjamin M. Scirica
EBEugene Braunwald
Eugene Braunwald
Itamar RazItamar Raz
Itamar Raz
MCMatthew A. Cavender
Matthew A. Cavender
DMDavid A. Morrow
David A. Morrow
DBDeepak L Bhatt
Deepak L Bhatt

24 March 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
KOKazuma Oyama
Kazuma Oyama
RGRobert P Giugliano
Robert P Giugliano
DBDavid D Berg
David D Berg
CRChristian T Ruff
Christian T Ruff
PJPetr Jarolim
Petr Jarolim
DMDavid A Morrow
David A Morrow
We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12 months and whether such changes from baseline to 12 months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding. ENGAGE AF-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2. We performed a nested prospective biomarker study in 6308 patients, analysing hsTnT, NT-proBNP, and GDF-15 at baseline and 12 months. hsTnT was dynamic in 46.9% (≥2 ng/L change), NT-proBNP in 51.9% (≥200 pg/mL change), GDF-15 in 45.6% (≥300 pg/mL change) during 12 months. In a Cox regression model, upward changes in log2-transformed hsTnT and NT-proBNP were associated with increased risk of S/SEE [adjusted hazard ratio (adj-HR) 1.74; 95% confidence interval (CI) 1.36–2.23 and adj-HR 1.27; 95% CI 1.07–1.50, respectively] and log2-transformed GDF-15 with bleeding (adj-HR 1.40; 95% CI 1.02–1.92). Reassessment of ABC-stroke (age, prior stroke/transient ischaemic attack, hsTnT, and NT-proBNP) and ABC-bleeding (age, prior bleeding, haemoglobin, hsTnT, and GDF-15) risk scores at 12 months accurately reclassified a significant proportion of patients compared with their baseline risk [net reclassification improvement (NRI) 0.50; 95% CI 0.36–0.65; NRI 0.42; 95% CI 0.33–0.51, respectively]. Serial assessment of hsTnT, NT-proBNP, and GDF-15 revealed that a substantial proportion of patients with AF had dynamic values. Greater increases in these biomarkers measured over 1 year are associated with important clinical outcomes in anticoagulated patients with AF. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation. hsTnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide; GDF-15, growth differentiation factor-15; AF, atrial fibrillation; ABC, age, biomarker, and clinical history.

9 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEva Seemanova
Eva Seemanova
RVRaymonda Varon
Raymonda Varon
JVJan Vejvalka
Jan Vejvalka
PJPetr Jarolim
Petr Jarolim
PSPavel Seeman
Pavel Seeman
MNMichael Nothnagel
Michael Nothnagel
The vast majority of patients with Nijmegen Breakage Syndrome (NBS) are of Slavic origin and carry a deleterious deletion (c.657del5; rs587776650) in the NBN gene on chromosome 8q21. This mutation is essentially confined to Slavic populations and may thus be considered a Slavic founder mutation. Notably, not a single parenthood of a homozygous c.657del5 carrier has been reported to date, while heterozygous carriers do reproduce but have an increased cancer risk. These observations seem to conflict with the considerable carrier frequency of c.657del5 of 0.5% to 1% as observed in different Slavic populations because deleterious mutations would be eliminated quite rapidly by purifying selection. Therefore, we propose that heterozygous c.657del5 carriers have increased reproductive success, i.e., that the mutation confers heterozygote advantage. In fact, in our cohort study of the reproductive history of 24 NBS pedigrees from the Czech Republic, we observed that female carriers gave birth to more children on average than female non-carriers, while no such reproductive differences were observed for males. We also estimate that c.657del5 likely occurred less than 300 generations ago, thus supporting the view that the original mutation predated the historic split and subsequent spread of the ‘Slavic people’. We surmise that the higher fertility of female c.657del5 carriers reflects a lower miscarriage rate in these women, thereby reflecting the role of the NBN gene product, nibrin, in the repair of DNA double strand breaks and their processing in immune gene rearrangements, telomere maintenance, and meiotic recombination, akin to the previously described role of the DNA repair genes BRCA1 and BRCA2.